Trailblazing Precision Oncology for Rare Tumor Subtypes

Molecular Tumor Boards seek to recommend therapeutics to patients based on varying levels of evidence linking specific genetic alterations to treatment response. This commentary highlights the study by Kato and colleagues, which reports the usage of precision medicine approaches in rare and ultra‐ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Shee, Kevin, Miller, Todd W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813755/
https://www.ncbi.nlm.nih.gov/pubmed/29158369
http://dx.doi.org/10.1634/theoncologist.2017-0494
_version_ 1783300230242893824
author Shee, Kevin
Miller, Todd W.
author_facet Shee, Kevin
Miller, Todd W.
author_sort Shee, Kevin
collection PubMed
description Molecular Tumor Boards seek to recommend therapeutics to patients based on varying levels of evidence linking specific genetic alterations to treatment response. This commentary highlights the study by Kato and colleagues, which reports the usage of precision medicine approaches in rare and ultra‐rare tumor subtypes, as well as the need to discover effective drugs for tumor subtypes without known targetable genetic alterations.
format Online
Article
Text
id pubmed-5813755
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-58137552018-02-21 Trailblazing Precision Oncology for Rare Tumor Subtypes Shee, Kevin Miller, Todd W. Oncologist Commentaries Molecular Tumor Boards seek to recommend therapeutics to patients based on varying levels of evidence linking specific genetic alterations to treatment response. This commentary highlights the study by Kato and colleagues, which reports the usage of precision medicine approaches in rare and ultra‐rare tumor subtypes, as well as the need to discover effective drugs for tumor subtypes without known targetable genetic alterations. AlphaMed Press 2017-11-20 2018-02 /pmc/articles/PMC5813755/ /pubmed/29158369 http://dx.doi.org/10.1634/theoncologist.2017-0494 Text en © AlphaMed Press 2017
spellingShingle Commentaries
Shee, Kevin
Miller, Todd W.
Trailblazing Precision Oncology for Rare Tumor Subtypes
title Trailblazing Precision Oncology for Rare Tumor Subtypes
title_full Trailblazing Precision Oncology for Rare Tumor Subtypes
title_fullStr Trailblazing Precision Oncology for Rare Tumor Subtypes
title_full_unstemmed Trailblazing Precision Oncology for Rare Tumor Subtypes
title_short Trailblazing Precision Oncology for Rare Tumor Subtypes
title_sort trailblazing precision oncology for rare tumor subtypes
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813755/
https://www.ncbi.nlm.nih.gov/pubmed/29158369
http://dx.doi.org/10.1634/theoncologist.2017-0494
work_keys_str_mv AT sheekevin trailblazingprecisiononcologyforraretumorsubtypes
AT millertoddw trailblazingprecisiononcologyforraretumorsubtypes

Ejemplares similares